دورية أكاديمية
Pharmacogenetic aspects of efficacy and safety of methotrexate treatment in pediatric acute lymphoblastic leukemia.
| العنوان: | Pharmacogenetic aspects of efficacy and safety of methotrexate treatment in pediatric acute lymphoblastic leukemia. |
|---|---|
| المؤلفون: | Gurieva OD; Department of Pediatric Oncology and Hematology Research Institute, N.N. Blokhin National Medical Research Cancer Center of the Ministry of Health of Russia, Moscow, Russia., Savelyeva MI; Department of Therapy, Institute of Continuous Professional Education, Yaroslavl State Medical University of the Ministry of Health of Russia, Yaroslavl, Russia., Valiev TT; Department of Pediatric Oncology and Hematology Research Institute, N.N. Blokhin National Medical Research Cancer Center of the Ministry of Health of Russia, Moscow, Russia.; Department of Oncology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia, Moscow, Russia., Sozaeva ZA; Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia, Moscow, Russia., Kondratenko SN; Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia, Moscow, Russia., Ilyin MV; Department of Therapy, Institute of Continuous Professional Education, Yaroslavl State Medical University of the Ministry of Health of Russia, Yaroslavl, Russia. |
| المصدر: | Drug metabolism and personalized therapy [Drug Metab Pers Ther] 2023 Dec 14; Vol. 38 (4), pp. 349-357. Date of Electronic Publication: 2023 Dec 14 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: De Gruyter Country of Publication: Germany NLM ID: 101653409 Publication Model: eCollection Cited Medium: Internet ISSN: 2363-8915 (Electronic) Linking ISSN: 23638915 NLM ISO Abbreviation: Drug Metab Pers Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin : De Gruyter, [2015]- |
| مواضيع طبية MeSH: | Methotrexate*/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics, Child ; Humans ; Polymorphism, Single Nucleotide ; Pharmacogenetics ; Risk Factors ; Genotype ; Liver-Specific Organic Anion Transporter 1/genetics |
| مستخلص: | Objectives: To evaluate the role of ABCB1 (C3435T rs1045642, rs1128503, rs2032582, rs4148738), SLCO1B1 T521C rs4149056 genetic polymorphisms in the development of major types of methotrexate (MTX) toxicities and the occurrence of a terminal event (death, relapse) in pediatric АLL. Methods: The study included 124 patients diagnosed with pediatric ALL. All patients treated according to the protocols of the German BFM group (2002/2009) with high-dose (1,000, 2,000 and 5,000 mg/m 2 ) methotrexate. MTX-related toxicities, including hematologic, hepatic and renal, were evaluated according to the common terminology criteria for adverse events version 5.0 (CTCAE v.5.0). Real-time PCR method was used to investigate polymorphisms of ABCB1 and SLCO1B1 genes. The study material was peripheral blood. Results: A competitive analysis demonstrated significant relationships between MTX ADRs. The results of the study support the existence of relationships between some ADRs and MTX kinetics. An associative analysis showed association with the development of AEs to methotrexate indicating their clinical significance from different genetic polymorphisms protein-transporters. The available results confirm the associations of the studied genes with the increased risk of high doses MTX toxic ADRs and terminal events. Conclusions: Complementing the existing criteria for pediatric ALL risk groups with pharmacogenetic indicators will allow further individualization of therapy. (© 2023 Walter de Gruyter GmbH, Berlin/Boston.) |
| References: | Howlader, N, Noone, AM, Krapcho, M, Miller, D, Brest, A, Yu, M, et al.. editors. SEER cancer statistics review, 1975–2016, Bethesda, MD: National Cancer Institute; 2016. SEER statistics. https://seer.cancer.gov›archive/csr/1975_2016/ [Accessed 24 Apr 2022]. Shervashidze, MA, Valiev, TT, Tupitsyn, NN. Prospects for evaluation of the minimal residual disease in the post-induction period in pediatric B-precursor acute lymphoblastic leukemia. Russ J Pediatr Hematol Oncol 2020;7:15–22. https://doi.org/10.21682/2311-1267-2020-7-2-15-22 . (PMID: 10.21682/2311-1267-2020-7-2-15-22) Terwilliger, T, Abdul-Hay, M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 2017;7:e577. https://doi.org/10.1038/bcj.2017.53 . (PMID: 10.1038/bcj.2017.53) Inaba, H, Greaves, M, Mullighan, CG. Acute lymphoblastic leukaemia. Lancet 2013;381:1943–55. https://doi.org/10.1016/s0140-6736(12)62187-4 . (PMID: 10.1016/s0140-6736(12)62187-4) Hilden, JM, Dinndorf, PA, Meerbaum, SO, Sather, H, Villaluna, D, Heerema, NA, et al.. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children’s Oncology Group. Blood 2006;108:441–51. https://doi.org/10.1182/blood-2005-07-3011 . (PMID: 10.1182/blood-2005-07-3011) Kotecha, RS, Gottardo, NG, Kees, UR, Cole, CH. The evolution of clinical trials for infant acute lymphoblastic leukemia. Blood Cancer J 2014;4:e200. https://doi.org/10.1038/bcj.2014.17 . (PMID: 10.1038/bcj.2014.17) Termuhlen, AM, Smith, LM, Perkins, SL, Lones, M, Finlay, JL, Weinstein, H, et al.. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children’s Oncology Group. Br J Haematol 2013;162:792–801. https://doi.org/10.1111/bjh.12460 . (PMID: 10.1111/bjh.12460) Howard, SC, McCormick, J, Pui, CH, Buddington, RK, Harvey, RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist 2016;21:1471–82. https://doi.org/10.1634/theoncologist.2015-0164 . (PMID: 10.1634/theoncologist.2015-0164) Children’s Oncology Group , Thompson, PA, Hwang, MF, Vargo, RC, Bomgaars, LR, Gerhart, JG, et al.. The population pharmacokinetics of high-dose methotrexate in infants with acute lymphoblastic leukemia highlight the need for bedside individualized dose adjustment: a report from the Children’s Oncology Group. Clin Pharmacokinet 2019;58:899–910. https://doi.org/10.1007/s40262-018-00734-0 . (PMID: 10.1007/s40262-018-00734-0) Lopez-Lopez, E, Autry, RJ, Smith, C, Yang, W, Paugh, SW, Panetta, JC, et al.. Pharmacogenomics of intracellular methotrexate polyglutamates in patients’ leukemia cells in vivo. J Clin Invest 2020;130:6600–15. https://doi.org/10.1172/jci140797 . (PMID: 10.1172/jci140797) Shen, DD, Azarnoff, DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 1978;3:1–13. https://doi.org/10.2165/00003088-197803010-00001 . (PMID: 10.2165/00003088-197803010-00001) Ramsey, LB, Panetta, JC, Smith, C, Yang, W, Fan, Y, Winick, NJ, et al.. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 2013;121:898–904. https://doi.org/10.1182/blood-2012-08-452839 . (PMID: 10.1182/blood-2012-08-452839) van de Steeg, E, van Esch, A, Wagenaar, E, Kenworthy, KE, Schinkel, AH. Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res 2013;19:821–32. https://doi.org/10.1158/1078-0432.ccr-12-2080 . (PMID: 10.1158/1078-0432.ccr-12-2080) Ramsey, LB, Bruun, GH, Yang, W, Treviño, LR, Vattathil, S, Scheet, P, et al.. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 2012;22:1–8. https://doi.org/10.1101/gr.129668.111 . (PMID: 10.1101/gr.129668.111) Rask, C, Albertioni, F, Bentzen, SM, Schroeder, H, Peterson, C. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia – a logistic regression analysis. Acta Oncol 1998;37:277–84. https://doi.org/10.1080/028418698429586 . (PMID: 10.1080/028418698429586) Mikkelsen, TS, Thorn, CF, Yang, JJ, Ulrich, CM, French, D, Zaza, G, et al.. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 2011;21:679–86. https://doi.org/10.1097/fpc.0b013e328343dd93 . (PMID: 10.1097/fpc.0b013e328343dd93) Schmiegelow, K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009;146:489–503. https://doi.org/10.1111/j.1365-2141.2009.07765.x . (PMID: 10.1111/j.1365-2141.2009.07765.x) Song, Z, Hu, Y, Liu, S, Jiang, D, Yi, Z, Benjamin, MM, et al.. The role of genetic polymorphisms in high-dose methotrexate toxicity and response in hematological malignancies: a systematic review and meta-analysis. Front Pharmacol 2021;12:757464. https://doi.org/10.3389/fphar.2021.757464 . (PMID: 10.3389/fphar.2021.757464) Maagdenberg, H, Oosterom, N, Zanen, J, Gemmati, D, Windsor, RE, Heil, SG, et al.. Genetic variants associated with methotrexate-induced mucositis in cancer treatment: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2021;161:103312. https://doi.org/10.1016/j.critrevonc.2021.103312 . (PMID: 10.1016/j.critrevonc.2021.103312) Yang, L, Hu, X, Xu, L. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumour Biol 2012;33:1445–54. https://doi.org/10.1007/s13277-012-0395-2 . (PMID: 10.1007/s13277-012-0395-2) Zhao, R, Diop-Bove, N, Visentin, M, Goldman, ID. Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr 2011;31:177–201. https://doi.org/10.1146/annurev-nutr-072610-145133 . (PMID: 10.1146/annurev-nutr-072610-145133) Zhu, C, Liu, YW, Wang, SZ, Li, XL, Nie, XL, Yu, XT, et al.. Associations between the C677T and A1298C polymorphisms of MTHFR and the toxicity of methotrexate in childhood malignancies: a meta-analysis. Pharmacogenomics J 2018;18:450–9. https://doi.org/10.1038/tpj.2017.34 . (PMID: 10.1038/tpj.2017.34) Ma, CX, Sun, YH, Wang, HY. ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate. Tumour Biol 2015;36:7599–606. https://doi.org/10.1007/s13277-015-3403-5 . (PMID: 10.1007/s13277-015-3403-5) Esmaili, MA, Kazemi, A, Faranoush, M, Mellstedt, H, Zaker, F, Safa, M, et al.. Polymorphisms within methotrexate pathway genes: relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia. Iran J Basic Med Sci 2020;23:800–9. https://doi.org/10.22038/ijbms.2020.41754.9858 . (PMID: 10.22038/ijbms.2020.41754.9858) Kato, T, Hamada, A, Mori, S, Saito, H. Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet 2012;27:192–9. https://doi.org/10.2133/dmpk.dmpk-11-rg-066 . (PMID: 10.2133/dmpk.dmpk-11-rg-066) Liu, SG, Gao, C, Zhang, RD, Zhao, XX, Cui, L, Li, WJ, et al.. Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Oncotarget 2017;8:37761–72. https://doi.org/10.18632/oncotarget.17781 . (PMID: 10.18632/oncotarget.17781) Martinez, D, Muhrez, K, Woillard, JB, Berthelot, A, Gyan, E, Choquet, S, et al.. Endogenous metabolites-mediated communication between OAT1/OAT3 and OATP1B1 may explain the association between SLCO1B1 SNPs and methotrexate toxicity. Clin Pharmacol Ther 2018;104:687–98. https://doi.org/10.1002/cpt.1008 . (PMID: 10.1002/cpt.1008) Yang, FF, Xue, TL, Gao, C, Wu, Y, Lin, W, Li, J, et al.. Effects of SLCO1B1 on elimination and toxicities of high-dose methotrexate in pediatric acute lymphoblastic leukemia. Pharmacogenomics 2022;23:821–34. https://doi.org/10.2217/pgs-2022-0098 . (PMID: 10.2217/pgs-2022-0098) Zhang, HN, He, XL, Wang, C, Wang, Y, Chen, YJ, Li, JX, et al.. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate. Pediatr Blood Cancer 2014;61:2203–7. https://doi.org/10.1002/pbc.25191 . (PMID: 10.1002/pbc.25191) |
| فهرسة مساهمة: | Keywords: ABCB1 and SLCO1B1 transporters; acute lymphoblastic leukemia; methotrexate; pharmacogenetics; polymorphism |
| المشرفين على المادة: | YL5FZ2Y5U1 (Methotrexate) 0 (SLCO1B1 protein, human) 0 (Liver-Specific Organic Anion Transporter 1) |
| تواريخ الأحداث: | Date Created: 20231215 Date Completed: 20240104 Latest Revision: 20240104 |
| رمز التحديث: | 20240104 |
| DOI: | 10.1515/dmpt-2023-0079 |
| PMID: | 38098143 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2363-8915 |
|---|---|
| DOI: | 10.1515/dmpt-2023-0079 |